Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Towa Pharmaceutical Co Ltd (Towa Pharmaceutical) manufactures and sells pharmaceutical products. It develops, manufactures, and distributes generic drugs. The company offers products such as vitamins, antibiotics and other drugs. Towa offers products in the therapeutic areas of gastroenterology, neurology, allergy, bacterial infections, chemotherapy, metabolism, hormone drugs, cardiology and respiratory. The company uses its proprietary technologies such as Ractab, a unique formulation technology for orally disintegrating (OD) tablets. The company also offers drug packaging and testing programs. It offers products in the form of tablets, capsules, injectables, patches, eye drops and others. The company sells its products through medical representatives. It operates through its sales offices in Sapporo, Aomori, Morioka, Sendai, Nagaoka, Nagano, Osaka, Tottori, and Nagasaki, among others. Towa is headquartered in Kadoma, Osaka, Japan.
Headquarters
Japan
Address
2-11, Shimbashi-Cho, Kadoma, Osaka, 571-8580
Website
www.towayakuhin.co.jp
Telephone
81 6 69009100
No of Employees
4,588
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4553 (TYO)
Revenue (2025)
$1.7B
13.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
17.4%
(2025 vs 2024)
Market Cap*
$1.2B
Net Profit Margin (2025)
XYZ
3.0%
(2025 vs 2024)
* As of and is in US$
Towa Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Drugs | Kusuri-no-Shiori |
| Vitamins | |
| Antibiotics | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Product Approvals | In September, the company and TIS Inc. launched Healthcare Passport. |
| 2025 | Contracts/Agreements | In August, the company entered into an agreement with Deloitte Tohmatsu to secure, advance, and internationalize talent in the accounting and finance field. |
| 2025 | Regulatory Approval | In August, the company received manufacturing and sales approval for six generic products covering five active ingredients: treatments for nail fungus, influenza (Tamiflu equivalent), epilepsy (Vimpat equivalent), hyperphosphatemia (Fosrenol equivalent), and antiallergic eye drops (Alesion equivalent). |
Competitor Comparison
| Key Parameters | Towa Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Sumitomo Pharma Co Ltd | ASKA Pharmaceutical Holdings Co Ltd | Daito Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Kadoma | Chuo-Ku | Osaka | Minato-Ku | Toyama |
| State/Province | Osaka | Tokyo | Osaka | Tokyo | Toyama |
| No. of Employees | 4,588 | 7,872 | 3,832 | 1,632 | 1,073 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Itsuro Yoshida | President; Director | Executive Board | - | - |
| Toshiyuki Tanaka | General Manager - External Affairs; Operating Officer | Senior Management | - | - |
| Norikazu Inoue | Division Manager - Administration; Operating Officer | Senior Management | - | - |
| Mitsuhiro Matsumoto | General Manager - Oncology & CNS Specialty Department; Operating Officer | Senior Management | - | - |
| Keisuke Hirai | Manager, Product Planning Unit | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer